The purpose of this study is to assess the safety of inhaled carbon monoxide (iCO) in intubated patients with sepsis-induced ARDS.
The acute respiratory distress syndrome (ARDS) is a syndrome of severe acute lung inflammation and hypoxemic respiratory failure with an incidence of 180,000 cases annually in the U.S.Despite decades of research and recent advances in lung protective ventilator strategies, morbidity and mortality remain unacceptably high. Furthermore, no specific effective pharmacologic therapies currently exist. The lack of specific effective therapies for sepsis-related ARDS indicates a need for new treatments that target novel pathways. Carbon monoxide (CO) represents a novel therapeutic modality in ARDS based on data obtained in experimental models of ARDS and sepsis over the past decade.
CO has been shown to be protective in experimental models of Acute Lung Injury (ALI), including hyperoxia and endotoxin exposure, bleomycin, ischemia/reperfusion, and ventilator-induced lung injury (VILI). At low doses, CO has been shown to confer tissue protective effects in these ALI models. In addition, CO has been shown to decrease inflammation, enhance phagocytosis, and improve mortality in models of sepsis including endotoxemia, hemorrhagic shock, and cecal ligation and puncture (CLP). CO has also been shown to have beneficial therapeutic effects in pre-clinical models of disease including pulmonary hypertension, vascular injury, and transplantation. Furthermore, multiple human studies have demonstrated that experimental administration of several different concentrations of CO is well tolerated and that low dose inhaled CO can be safely administered to subjects in a controlled research environment.
The purpose of this study is to assess the safety of inhaled CO therapy in mechanically ventilated patients with sepsis-induced ARDS.
| Condition | ADULT RESPIRATORY DISTRESS SYNDROME |
|---|---|
| Treatment | Inhaled Carbon Monoxide at 100ppm, Placebo for Inhaled Carbon Monoxide at 100ppm, Inhaled Carbon Monoxide at 200ppm, Algorthim Specified dose of iCO to achieve COHb of 6-8%, Placebo for Inhaled Carbon Monoxide at 200ppm, Placebo for Cohort 3, Open-label algorithm-specified dose of iCO to achieve COHb of 6-8%, Inhaled Carbon Monoxide at 100ppm (4 participants), Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants), Inhaled Carbon Monoxide at 200ppm (4 participants), Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants), Open-label algorithm-specified dose of iCO to achieve COHb of 6-8% (6 participants) |
| Clinical Study Identifier | NCT02425579 |
| Sponsor | Brigham and Women's Hospital |
| Last Modified on | 23 January 2021 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.